Navigation Links
DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Date:9/8/2009

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis. The award will provide DOR with approximately $500,000 over a two-year period.

The grant application included the Phase 1/2 protocol BDP-ENT-01, which is designed as a multicenter, open-label, sequential, dose-escalation study in approximately 36 patients. Patients with rectal cancer who are scheduled to undergo concurrent radiation and chemotherapy prior to surgery will be enrolled in four dose groups. The objectives of the study are to evaluate the safety and maximal tolerated dose of escalating doses of DOR201, as well as the preliminary efficacy of DOR201 for prevention of signs and symptoms of acute radiation enteritis. The study is expected to be initiated in 2009.

Acute radiation enteritis is caused by radiation-induced death of cells in the lining of the bowel. As bowel cells die and are not replaced, gastrointestinal toxicity develops over the next few days and weeks due to an inflammatory response to dead cells and bacteria, with chronic diarrhea, vomiting and pain being the major symptoms. The addition of chemotherapy often exacerbates the onset, severity and debilitation related to intestinal symptoms. Radiation enteritis often results in delay or interruption of the cancer treatment. There are over 100,000 patients annually in the United States who receive abdominal or pelvic external beam radiation treatment for cancer, and these patients are at risk of developing acute and chronic radiation enteritis.

"Radi
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
5. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... BOCA RATON, Fla. , July 29, 2015 ... immediate launch of Azelastine HCl Nasal Solution, 0.1%. The ... this Abbreviated New Drug Application (ANDA), which is ... Meda Pharmaceuticals. Azelastine hydrochloride nasal solution (nasal spray) ... on June 2015 IMS Health sales data.  Azelastine ...
(Date:7/29/2015)... , July 29, 2015 ... research report "Global Industry Insight: Microfluidic Devices ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles. ... Microfluidic devices  ...
(Date:7/29/2015)... , July 29, 2015 Commenting ... transaction closed, CFO Simon Dingemans reveals sales ... are performing in line with expectations. Ahead of a ... to sustainable innovation. The interview and transcript ... MerchantCantos produces in-depth interviews, documentaries and webcasts with senior ...
Breaking Medicine Technology:Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 3Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 5
... The drug imatinib,mesylate, more commonly known as Gleevec(R), ... with an advanced form of chronic myeloid leukemia,(CML), according ... of the American Society of Hematology., A team ... drug,s,creator, Brian Druker, MD, followed 454 patients with chronic-phase ...
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
Cached Medicine Technology:Leukemia Drug Proves Safe and Effective Over the Long Term 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3
(Date:7/29/2015)... ... July 29, 2015 , ... The healthcare analytics market is ... region. Factors such as the rising pressure to curb healthcare costs, big data ... venture capital investments are driving market growth. Check 149 data tables & 57 ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to The Spirits Business on ... directly responsible for stimulating and perpetuating alcohol use disorders. Humans have the same gene, ... the National academy of Sciences, and has given researchers inklings to explore Rsu1 in ...
(Date:7/29/2015)... ... 2015 , ... According to the Miami Herald on July 18th ... health disorders. Acu-detox may begin taking off in the South Florida community as more ... Although acupuncture is not a new practice, it is not widely used, but has ...
(Date:7/29/2015)... ... 29, 2015 , ... San Fernando Valley skin doctor , Dr. Peyman ... only, patients can get the complete treatment process with a 10 percent discount on ... treatment and have loose or sagging skin. , As the only non-surgical procedure ...
(Date:7/29/2015)... ... July 29, 2015 , ... Today marks a significant achievement in bringing ... growth companies and is led by a group of experienced investors, has tapped into ... with their dollars to be a part of the fund. The Sofia Fund ...
Breaking Medicine News(10 mins):Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 2Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 3Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 4Health News:Healthcare Analytics Market Growing at 26.5% CAGR to 2020 5Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Sofia Fund Surpasses Investor Goals 2
... test to assess chest pain is accurate in more rapid ... a heart attack. It can be caused by indigestion or ... a medical emergency, and a series of tests is given ... a heart attack.// , These tests normally take a ...
... be better than white at fending off fungi and ... it could explain why dark skin evolved in humans ... theory on why darker skin prevailed in some areas ... melanin in darker skin protects against cancer and sunburn ...
... Duke University in the United States, depression increases the ... depression and coronary artery disease is well established and ... 357 patients diagnosed with heart failure for depression. They ... suffering from major depression. Patients who were not depressed ...
... in this week’s British Medical Journal shows that bacteria with ... for ear infections can be used successfully and may help ... one of the most common bacterial infections in young children, ... is caused by the spread of Streptococcus pneumoniae and other ...
... Britain examining the relationship between increasing rates of testicular ... have infertility problems have an increased risk of developing ... of the British Medical Journal (BMJ), the study found ... the subsequent risk of testicular cancer, with men in ...
... factor for most cancers, says a Stanford University Medical Centre ... have a genetic component than those diagnosed later. , , Rare ... familial than breast and lung cancer.// The model assumed that ... of several relatively rare genes. , , The new model ...
Cached Medicine News:
... Leg Brace features a multi-axial hinge that ... without altering kinematics. The infinite degree of ... flexion and extension control of the knee. ... the tibia in correct anatomical alignment. The ...
... combines the therapeutic benefits of controlled compression ... to minimize pain. The cuff is anatomically ... maximum cryotherapy.,All Cryo/Cuffs can be ordered as ... (including a tube assembly and insulation disk). ...
... lightweight orthosis is designed to comfortably ... while allowing unobstructed motion of the ... custom fit the splint may be ... using a heat gun. One cotton ...
FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession...
Medicine Products: